Microscopic view of infant's gut, illustrating the balance of gut microbiota in relation to infant health.

Gut Microbiome and Infant Health: New Insights into Cholestasis

Soraya Malik in Health & Wellness September 2025 • 4 min read.

"Decoding the connection between gut bacteria and liver function in infants with cholestasis."

Cholestasis, a condition where bile flow is impaired, poses a significant threat to infant health, with its incidence on the rise. While the connection between gut microbiota (GM) and liver diseases like cirrhosis and non-alcoholic steatohepatitis is increasingly recognized, understanding the specific role of GM in infants with cholestasis has remained limited.

A groundbreaking study published in Frontiers in Microbiology delves into this intricate relationship, comparing the GM composition of 43 infants with cholestasis (IC group) against 37 healthy infants (H group). Researchers employed 16S rDNA analysis to identify key differences and correlations between GM and hepatic function.

The findings reveal a landscape of altered bacterial communities in infants with cholestasis, opening new avenues for early diagnosis and targeted treatments.

How Does Gut Microbiome Impact Infants Health?

Microscopic view of infant's gut, illustrating the balance of gut microbiota in relation to infant health.

The study identified a significant decrease in bacterial diversity within the IC group compared to the H group. Further analysis pinpointed 13 genera that were differentially enriched between the two groups. Notably, Bifidobacterium, Bacteroides, Streptococcus, Enterococcus, and Staphylococcus exhibited distinct patterns of abundance.

Healthy infants typically exhibit a gut environment where Faecalibacterium and Erysipelatoclostridium correlate positively, this beneficial relationship was absent in IC patients. Instead, the IC group displayed a more complex GM co-occurrence network, characterized by three core nodes: Phyllobacterium, Ruminococcus, and Anaerostipes.

Decreased Diversity: Infants with cholestasis showed less variety in their gut bacteria compared to healthy infants.
Key Genera Imbalance: Certain types of bacteria, like Bifidobacterium and Bacteroides, were less abundant, while others, such as Streptococcus and Staphylococcus, were more prevalent.
Disrupted Bacterial Relationships: The typical positive interaction between Faecalibacterium and Erysipelatoclostridium was missing in infants with cholestasis.

By leveraging GM composition, researchers achieved high accuracy in distinguishing cholestatic patients from healthy infants [areas under receiver operating curve (AUC) > 0.97]. Rothia, Eggerthella, Phyllobacterium, and Blautia emerged as valuable biomarkers for this differentiation.

The Future of Infant Cholestasis Treatment

This study marks a significant stride toward understanding the intricate interplay between GM and cholestasis in infants. The identification of potential biomarkers paves the way for non-invasive diagnostic tools, while insights into altered GM composition open doors for innovative therapeutic strategies, such as targeted probiotic interventions. Further research is needed to fully translate these findings into clinical practice, the study provides a robust foundation for improving the diagnosis and treatment of infantile cholestasis.

About this Article -

This article was crafted using a human-AI hybrid and collaborative approach. AI assisted our team with initial drafting, research insights, identifying key questions, and image generation. Our human editors guided topic selection, defined the angle, structured the content, ensured factual accuracy and relevance, refined the tone, and conducted thorough editing to deliver helpful, high-quality information.See our About page for more information.

Everything You Need To Know

What is the connection between the Gut Microbiome and Cholestasis in infants?

The study reveals a significant connection between the Gut Microbiome (GM) and Cholestasis in infants. Infants with Cholestasis (IC group) exhibited altered bacterial communities compared to healthy infants (H group). The research identified a decrease in bacterial diversity and imbalances in key genera. For instance, Bifidobacterium and Bacteroides were less abundant in the IC group, while Streptococcus and Staphylococcus were more prevalent. Additionally, the typical positive relationship between Faecalibacterium and Erysipelatoclostridium, observed in healthy infants, was absent in the IC patients. These alterations in the GM composition are associated with the impaired bile flow characteristic of Cholestasis.

How did the researchers identify differences in the Gut Microbiome of infants with Cholestasis?

Researchers employed 16S rDNA analysis to compare the Gut Microbiome (GM) composition of 43 infants with Cholestasis (IC group) against 37 healthy infants (H group). This method allowed them to identify key differences and correlations between the GM and hepatic function. Through this analysis, they were able to pinpoint alterations in bacterial communities, including decreased bacterial diversity and imbalances in specific genera. The study also identified specific bacterial genera, such as Rothia, Eggerthella, Phyllobacterium, and Blautia, that emerged as valuable biomarkers for distinguishing between cholestatic patients and healthy infants.

What are the implications of altered bacterial relationships in infants with Cholestasis?

In healthy infants, Faecalibacterium and Erysipelatoclostridium typically exhibit a positive correlation. This beneficial relationship, however, was absent in infants with Cholestasis (IC group). Instead, the IC group displayed a more complex GM co-occurrence network, characterized by three core nodes: Phyllobacterium, Ruminococcus, and Anaerostipes. This disruption suggests an imbalance in the gut environment, potentially impacting the overall health and liver function in these infants. The absence of the beneficial relationship and the presence of alternative bacterial interactions underscore the significant changes in the GM associated with Cholestasis, highlighting the potential for targeted interventions to restore a healthy gut balance.

What potential biomarkers were identified in the study for diagnosing Cholestasis in infants?

The study identified several potential biomarkers for diagnosing Cholestasis in infants. Researchers found that by leveraging Gut Microbiome (GM) composition, they could distinguish cholestatic patients from healthy infants with high accuracy. Specific bacterial genera, including Rothia, Eggerthella, Phyllobacterium, and Blautia, emerged as valuable biomarkers. The presence or absence, and the relative abundance of these genera can serve as indicators of the disease, potentially leading to non-invasive diagnostic tools.

How can the study's findings improve the treatment of infant Cholestasis?

The study's findings open doors for innovative therapeutic strategies. The identification of altered Gut Microbiome (GM) composition in infants with Cholestasis (IC group) provides insights into the disease's underlying mechanisms. This knowledge paves the way for targeted probiotic interventions aimed at restoring a healthier gut environment. By understanding the specific bacterial imbalances, such as the decrease in Bifidobacterium and Bacteroides, and the disruption of the Faecalibacterium and Erysipelatoclostridium relationship, researchers can develop treatments to restore a balance within the infant gut. The identification of potential biomarkers also facilitates early diagnosis, allowing for timely interventions to manage the condition effectively, ultimately improving the diagnosis and treatment of infantile Cholestasis.